Gan & Lee Pharmaceuticals. (SHA: 603087)
China flag China · Delayed Price · Currency is CNY
46.58
-0.44 (-0.94%)
Nov 21, 2024, 10:00 AM CST

Gan & Lee Pharmaceuticals. Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
2,9362,5961,7103,6123,3622,895
Upgrade
Other Revenue
11.611.62.40.11--
Upgrade
Revenue
2,9472,6081,7123,6123,3622,895
Upgrade
Revenue Growth (YoY)
23.78%52.31%-52.60%7.44%16.12%21.26%
Upgrade
Cost of Revenue
796.76724.7443.93399.9309.82237.98
Upgrade
Gross Profit
2,1511,8831,2683,2123,0522,657
Upgrade
Selling, General & Admin
1,3191,1631,3341,3021,2011,075
Upgrade
Research & Development
534.52501.02562.47474.59419.99235.56
Upgrade
Other Operating Expenses
27.823.6120.3726.2120.9816.26
Upgrade
Operating Expenses
1,9011,7031,9441,8221,6371,328
Upgrade
Operating Income
249.64180.04-675.681,3901,4151,329
Upgrade
Interest Expense
-0.55-0.55-0.78-0.96--
Upgrade
Interest & Investment Income
126.99141.01186.63321.9967.3846.71
Upgrade
Currency Exchange Gain (Loss)
2.42.4-2.39-0.710.26-4.68
Upgrade
Other Non Operating Income (Expenses)
5.39-0.8-1.6-3.34-3.83-3.4
Upgrade
EBT Excluding Unusual Items
383.87322.09-493.821,7071,4791,368
Upgrade
Gain (Loss) on Sale of Investments
167.56-17.92-80.66-54.45-42.7722.39
Upgrade
Gain (Loss) on Sale of Assets
0.12-0.49-5.18-1.7-6.52-1.68
Upgrade
Asset Writedown
-9.18-12.55-40.92---
Upgrade
Other Unusual Items
16.3515.0138.144.9616.129
Upgrade
Pretax Income
558.72306.14-582.471,6961,4451,397
Upgrade
Income Tax Expense
-22.3-34.09-142.96243.26214.76230.19
Upgrade
Earnings From Continuing Operations
581.02340.23-439.521,4531,2311,167
Upgrade
Minority Interest in Earnings
-0.16-0.160000
Upgrade
Net Income
580.86340.07-439.521,4531,2311,167
Upgrade
Net Income to Common
580.86340.07-439.521,4531,2311,167
Upgrade
Net Income Growth
141.25%--18.04%5.43%24.98%
Upgrade
Shares Outstanding (Basic)
589567563561533505
Upgrade
Shares Outstanding (Diluted)
589567563561533505
Upgrade
Shares Change (YoY)
3.48%0.59%0.46%5.28%5.43%0.09%
Upgrade
EPS (Basic)
0.990.60-0.782.592.312.31
Upgrade
EPS (Diluted)
0.990.60-0.782.592.312.31
Upgrade
EPS Growth
133.14%--12.12%0%24.86%
Upgrade
Free Cash Flow
150.74-443.61-686.76386.09659.2750.97
Upgrade
Free Cash Flow Per Share
0.26-0.78-1.220.691.241.49
Upgrade
Dividend Per Share
0.2000.200-0.3000.4000.357
Upgrade
Dividend Growth
----25.00%12.01%-
Upgrade
Gross Margin
72.97%72.21%74.07%88.93%90.78%91.78%
Upgrade
Operating Margin
8.47%6.90%-39.46%38.49%42.08%45.91%
Upgrade
Profit Margin
19.71%13.04%-25.67%40.22%36.61%40.32%
Upgrade
Free Cash Flow Margin
5.11%-17.01%-40.11%10.69%19.61%25.94%
Upgrade
EBITDA
478.21394.57-479.871,5711,5741,445
Upgrade
EBITDA Margin
16.23%15.13%-28.03%43.49%46.83%49.91%
Upgrade
D&A For EBITDA
228.57214.53195.81180.64159.6115.83
Upgrade
EBIT
249.64180.04-675.681,3901,4151,329
Upgrade
EBIT Margin
8.47%6.90%-39.46%38.49%42.08%45.91%
Upgrade
Effective Tax Rate
---14.34%14.86%16.47%
Upgrade
Revenue as Reported
2,9472,6081,7123,6123,3622,895
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.